These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 9819405)

  • 1. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.
    Gelmetti V; Zhang J; Fanelli M; Minucci S; Pelicci PG; Lazar MA
    Mol Cell Biol; 1998 Dec; 18(12):7185-91. PubMed ID: 9819405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors.
    Lutterbach B; Westendorf JJ; Linggi B; Patten A; Moniwa M; Davie JR; Huynh KD; Bardwell VJ; Lavinsky RM; Rosenfeld MG; Glass C; Seto E; Hiebert SW
    Mol Cell Biol; 1998 Dec; 18(12):7176-84. PubMed ID: 9819404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.
    Wang J; Hoshino T; Redner RL; Kajigaya S; Liu JM
    Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10860-5. PubMed ID: 9724795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein.
    Melnick AM; Westendorf JJ; Polinger A; Carlile GW; Arai S; Ball HJ; Lutterbach B; Hiebert SW; Licht JD
    Mol Cell Biol; 2000 Mar; 20(6):2075-86. PubMed ID: 10688654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.
    Amann JM; Nip J; Strom DK; Lutterbach B; Harada H; Lenny N; Downing JR; Meyers S; Hiebert SW
    Mol Cell Biol; 2001 Oct; 21(19):6470-83. PubMed ID: 11533236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple regions of ETO cooperate in transcriptional repression.
    Hildebrand D; Tiefenbach J; Heinzel T; Grez M; Maurer AB
    J Biol Chem; 2001 Mar; 276(13):9889-95. PubMed ID: 11150306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.
    Barseguian K; Lutterbach B; Hiebert SW; Nickerson J; Lian JB; Stein JL; van Wijnen AJ; Stein GS
    Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15434-9. PubMed ID: 12427969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.
    Erickson PF; Dessev G; Lasher RS; Philips G; Robinson M; Drabkin HA
    Blood; 1996 Sep; 88(5):1813-23. PubMed ID: 8781439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.
    Ibañez V; Sharma A; Buonamici S; Verma A; Kalakonda S; Wang J; Kadkol S; Saunthararajah Y
    Cancer Res; 2004 Jul; 64(13):4547-54. PubMed ID: 15231665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.
    Steffen B; Serve H; Berdel WE; Agrawal S; Linggi B; Büchner T; Hiebert SW; Müller-Tidow C
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8448-53. PubMed ID: 12819347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.
    Salat D; Liefke R; Wiedenmann J; Borggrefe T; Oswald F
    Mol Cell Biol; 2008 May; 28(10):3502-12. PubMed ID: 18332109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ETO interacting proteins.
    Hug BA; Lazar MA
    Oncogene; 2004 May; 23(24):4270-4. PubMed ID: 15156183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation.
    Minucci S; Maccarana M; Cioce M; De Luca P; Gelmetti V; Segalla S; Di Croce L; Giavara S; Matteucci C; Gobbi A; Bianchini A; Colombo E; Schiavoni I; Badaracco G; Hu X; Lazar MA; Landsberger N; Nervi C; Pelicci PG
    Mol Cell; 2000 May; 5(5):811-20. PubMed ID: 10882117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development.
    Yan M; Burel SA; Peterson LF; Kanbe E; Iwasaki H; Boyapati A; Hines R; Akashi K; Zhang DE
    Proc Natl Acad Sci U S A; 2004 Dec; 101(49):17186-91. PubMed ID: 15569932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligomerization of ETO is obligatory for corepressor interaction.
    Zhang J; Hug BA; Huang EY; Chen CW; Gelmetti V; Maccarana M; Minucci S; Pelicci PG; Lazar MA
    Mol Cell Biol; 2001 Jan; 21(1):156-63. PubMed ID: 11113190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ETO (MTG8) gene family.
    Davis JN; McGhee L; Meyers S
    Gene; 2003 Jan; 303():1-10. PubMed ID: 12559562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.
    Melnick A; Carlile GW; McConnell MJ; Polinger A; Hiebert SW; Licht JD
    Blood; 2000 Dec; 96(12):3939-47. PubMed ID: 11090081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.
    Heibert SW; Lutterbach B; Durst K; Wang L; Linggi B; Wu S; Wood L; Amann J; King D; Hou Y
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S31-4. PubMed ID: 11587363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.
    Guo C; Li J; Steinauer N; Wong M; Wu B; Dickson A; Kalkum M; Zhang J
    J Biol Chem; 2020 Mar; 295(13):4212-4223. PubMed ID: 32071087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.